LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Abnormal functional connectivity in radiologically isolated syndrome: A resting-state fMRI study.

    Benito-León, Julián / Del Pino, Ana Belén / Aladro, Yolanda / Cuevas, Constanza / Domingo-Santos, Ángela / Galán Sánchez-Seco, Victoria / Labiano-Fontcuberta, Andrés / Gómez-López, Ana / Salgado-Cámara, Paula / Costa-Frossard, Lucienne / Monreal, Enrique / Sainz de la Maza, Susana / Matías-Guiu, Jordi A / Matías-Guiu, Jorge / Delgado-Álvarez, Alfonso / Montero-Escribano, Paloma / Martínez-Ginés, María Luisa / Higueras, Yolanda / Ayuso-Peralta, Lucía /
    Malpica, Norberto / Melero, Helena

    Multiple sclerosis (Houndmills, Basingstoke, England)

    2023  Volume 29, Issue 11-12, Page(s) 1393–1405

    Abstract: Background: Radiologically isolated syndrome (RIS) patients might have psychiatric and cognitive deficits, which suggests an involvement of major resting-state functional networks. Notwithstanding, very little is known about the neural networks involved ...

    Abstract Background: Radiologically isolated syndrome (RIS) patients might have psychiatric and cognitive deficits, which suggests an involvement of major resting-state functional networks. Notwithstanding, very little is known about the neural networks involved in RIS.
    Objective: To examine functional connectivity differences between RIS and healthy controls using resting-state functional magnetic resonance imaging (fMRI).
    Methods: Resting-state fMRI data in 25 RIS patients and 28 healthy controls were analyzed using an independent component analysis; in addition, seed-based correlation analysis was used to obtain more information about specific differences in the functional connectivity of resting-state networks. Participants also underwent neuropsychological testing.
    Results: RIS patients did not differ from the healthy controls regarding age, sex, and years of education. However, in memory (verbal and visuospatial) and executive functions, RIS patients' cognitive performance was significantly worse than the healthy controls. In addition, fluid intelligence was also affected. Twelve out of 25 (48%) RIS patients failed at least one cognitive test, and six (24.0%) had cognitive impairment. Compared to healthy controls, RIS patients showed higher functional connectivity between the default mode network and the right middle and superior frontal gyri and between the central executive network and the right thalamus (
    Conclusion: RIS patients had abnormal brain connectivity in major resting-state neural networks and worse performance in neurocognitive tests. This entity should be considered not an "incidental finding" but an exclusively non-motor (neurocognitive) variant of multiple sclerosis.
    MeSH term(s) Humans ; Brain Mapping/methods ; Magnetic Resonance Imaging/methods ; Brain/pathology ; Gyrus Cinguli ; Parietal Lobe ; Neural Pathways/diagnostic imaging
    Language English
    Publishing date 2023-09-29
    Publishing country England
    Document type Journal Article
    ZDB-ID 1290669-4
    ISSN 1477-0970 ; 1352-4585
    ISSN (online) 1477-0970
    ISSN 1352-4585
    DOI 10.1177/13524585231195851
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4428: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.

    Sainz de la Maza, Susana / Sabin Muñoz, Julia / Pilo de la Fuente, Belén / Thuissard, Israel / Andreu-Vázquez, Cristina / Galán Sánchez-Seco, Victoria / Salgado-Cámara, Paula / Costa-Frossard, Lucienne / Monreal, Enric / Ayuso-Peralta, Lucía / García-Vasco, Lorena / García-Domínguez, José Manuel / Martínez-Ginés, María Luisa / Muñoz Fernández, Carmen / Díaz-Díaz, Judit / Oreja-Guevara, Celia / Gómez-Moreno, Mayra / Martín, Hugo / Rubio-Flores, Laura /
    Blasco, María Rosario / Villar-Guimerans, Luisa María / Aladro, Yolanda

    Multiple sclerosis and related disorders

    2022  Volume 59, Page(s) 103669

    Abstract: Background: Lymphopenia is a major concern in MS patients treated with dimethyl-fumarate (DMF) as it increases the risk of progressive multifocal leukoencephalopathy. A pronounced reduction in absolute lymphocyte counts (ALCs) early after treatment ... ...

    Abstract Background: Lymphopenia is a major concern in MS patients treated with dimethyl-fumarate (DMF) as it increases the risk of progressive multifocal leukoencephalopathy. A pronounced reduction in absolute lymphocyte counts (ALCs) early after treatment initiation has been suggested to be associated with the occurrence of lymphopenia thereafter.
    Objectives: To identify risk factors for DMF-induced lymphopenia and evaluate whether the degree of decrease in the ALCs three months after initiation of DMF treatment is a predictor of the subsequent development of lymphopenia.
    Methods: In this real-world Spanish prospective multicenter study conducted in MS patients who started DMF between 2014 and 2019, we analyzed the association between DMF-related lymphopenia and the percentage of early ALCs decline using regression models, considering both, significant lymphopenia (grades 2 + 3) and severe lymphopenia (grade 3). The cutoff values of early ALCs declines were obtained using the ROC curve.
    Results: Among 532 MS patients treated with DMF, 193 (36.3%) developed any grade of lymphopenia. Older age and lower ALCs at treatment onset predicted the risk for lymphopenia but the best predictive risk factor was the reduction of ALCs within the three first months of treatment. Specifically, a reduction in ALCs≥21.2% was associated with a 6.5-fold higher risk of developing significant lymphopenia, and a decrease in ALCs≥40.2% with a 12.7-fold higher risk of developing severe lymphopenia.
    Conclusions: A pronounced reduction in ALCs early after initiation of DMF in MS patients is the best predictive risk factor for the subsequent development of significant lymphopenia.
    MeSH term(s) Dimethyl Fumarate/adverse effects ; Humans ; Immunosuppressive Agents/adverse effects ; Lymphopenia/chemically induced ; Multiple Sclerosis/chemically induced ; Multiple Sclerosis/complications ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis, Relapsing-Remitting/chemically induced ; Multiple Sclerosis, Relapsing-Remitting/complications ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Prospective Studies ; Risk Factors
    Chemical Substances Immunosuppressive Agents ; Dimethyl Fumarate (FO2303MNI2)
    Language English
    Publishing date 2022-02-04
    Publishing country Netherlands
    Document type Journal Article ; Multicenter Study
    ZDB-ID 2645330-7
    ISSN 2211-0356 ; 2211-0348
    ISSN (online) 2211-0356
    ISSN 2211-0348
    DOI 10.1016/j.msard.2022.103669
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Fingolimod Use for the Treatment of Multiple Sclerosis in a Clinical Practice Setting in Madrid.

    Galán Sánchez-Seco, Victoria / Casanova-Peño, Ignacio / Álvarez-Lafuente, Roberto / Sánchez-Jiménez, Mónica / García-Martínez, Ángel / Domínguez-Mozo, María Inmaculada / Arias-Leal, Ana María / García-Montojo, Marta / Arroyo-González, Rafael

    Clinical neuropharmacology

    2017  Volume 40, Issue 1, Page(s) 29–33

    Abstract: Objective: To assess the effectiveness and safety of fingolimod use in a Spanish clinical practice setting.: Methods: Retrospective study with multiple sclerosis patients who received at least 1 fingolimod dose between January 2004 and January 2015. ... ...

    Abstract Objective: To assess the effectiveness and safety of fingolimod use in a Spanish clinical practice setting.
    Methods: Retrospective study with multiple sclerosis patients who received at least 1 fingolimod dose between January 2004 and January 2015. Effectiveness and safety data were collected during the entire treatment of each patient. Analysis was performed for the total population and stratified according to prior treatment, sex, and age at treatment initiation.
    Results: A total of 167 patients were included, 50.9% had prior immunomodulator use, 33.5% natalizumab use, and 15.6% were naive patients. The annual relapse rate (ARR) decreased for the total population at month 12 (62%) and month 24 (84%) (P < 0.0001, in both cases); for naive patients (P < 0.05) and patients with prior immunomodulator use (P < 0.0001); for patients with prior natalizumab use, the ARR kept low after treatment initiation (0.23). After 24 months, the proportion of relapse-free patients was 70% or greater and disability progression-free patients was 80% or greater. No significant differences were observed when the results were compared by prior treatment, sex, or age. Thirty-two patients (19.2%) reported adverse drug reactions and 9.6% discontinued: 4.8% due to adverse drug reactions and 4.8% for lack of effectiveness.
    Conclusions: The results support fingolimod use due to clinical effectiveness, tolerability, and ease of administration.
    MeSH term(s) Adult ; Disability Evaluation ; Female ; Fingolimod Hydrochloride/therapeutic use ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Middle Aged ; Multiple Sclerosis/drug therapy ; Recurrence ; Retrospective Studies ; Spain ; Time Factors ; Treatment Outcome
    Chemical Substances Immunosuppressive Agents ; Fingolimod Hydrochloride (G926EC510T)
    Language English
    Publishing date 2017-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 199293-4
    ISSN 1537-162X ; 0362-5664
    ISSN (online) 1537-162X
    ISSN 0362-5664
    DOI 10.1097/WNF.0000000000000196
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 437: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Drug-Related Eyelid Nystagmus: Two Cases of a Rare Clinical Phenomenon Related to Carbamazepine and Derivatives.

    Matarazzo, Michele / Galán Sánchez-Seco, Victoria / Méndez-Guerrero, Antonio José / Gata-Maya, David / Domingo-Santos, Ángela / Ruiz-Morales, Juan / Benito-León, Julián

    Clinical neuropharmacology

    2016  Volume 39, Issue 1, Page(s) 49–50

    Abstract: Background: Eyelid nystagmus is a rare clinical phenomenon described mostly related to brainstem or cerebellum lesions. The mechanism of this phenomenon is incompletely understood.: Patients and methods: We report 2 cases of eyelid nystagmus induced ... ...

    Abstract Background: Eyelid nystagmus is a rare clinical phenomenon described mostly related to brainstem or cerebellum lesions. The mechanism of this phenomenon is incompletely understood.
    Patients and methods: We report 2 cases of eyelid nystagmus induced by carbamazepine and oxcarbazepine intoxication.
    Conclusions: Carbamazepine and derivatives may induce eyelid nystagmus in the setting of acute intoxication. To the best of our knowledge, these are the first cases of drug-related eyelid nystagmus.
    MeSH term(s) Aged ; Anticonvulsants/adverse effects ; Carbamazepine/adverse effects ; Epilepsy/drug therapy ; Female ; Humans ; Middle Aged ; Nystagmus, Pathologic/chemically induced
    Chemical Substances Anticonvulsants ; Carbamazepine (33CM23913M)
    Language English
    Publishing date 2016-01
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 199293-4
    ISSN 1537-162X ; 0362-5664
    ISSN (online) 1537-162X
    ISSN 0362-5664
    DOI 10.1097/WNF.0000000000000125
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 437: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top